# Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

> **NCT00885664** · PHASE4 · COMPLETED · sponsor: **University of Cincinnati** · enrollment: 60 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Truvada (tenofovir/emtricitabine)
- **DRUG:** Kaletra (lopinavir/ritonavir)

## Key facts

- **NCT ID:** NCT00885664
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2009-09
- **Final completion:** 2010-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885664, "Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00885664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*